Transcript Highlights:

• law, food producers may, if they have an ingredient they want to get into food, either submit to the FDA
• Red Dye No. 3 has been banned for more than a decade in cosmetics, but somehow the FDA has left it for
• When you can ask the FDA to determine that something's generally recognized as safe, and if you do that
• If the FDA is reviewing the substance, it has no effect at all.
• FDA recommend, et cetera. But it must be there is a language.

Keywords: 993, senate, all

Summary: The Agriculture Committee met for its first 2026 meeting and took up a full agenda of bills focused on food safety, agricultural programs, consumer transparency, and farm-related policy. Early measures included S.592 on a youth and agriculture entrepreneurship summer employment program, which was reported to finance without opposition, and S.1239E, the Food Safety and Technical Disclosure Act, which would require disclosure of certain food ingredients to the state and public and also ban three substances outright. Senator Kavanaugh described the bill as closing a loophole in federal food safety law; Senator Borrello opposed it as a state-by-state approach that could raise costs and disrupt the supply chain, while Senator O’Rourke supported it as a science-based measure with available substitutes. The bill was reported back to the board with one no vote and one without recommendation. The committee also advanced S.1783A on liquefied petroleum/propane fee disclosures, with supporters saying it would prevent consumers from being charged for improper or hidden fees and opponents arguing it should not single out state-related charges; the bill moved to the board. S.4041, creating a sanitary retail food store grant program, was reported to finance. S.4162, relating to the Fresh Connect program and local produce purchases, prompted discussion about whether state resources should instead be concentrated on the Double Up Food Bucks program; sponsors said both programs are needed and that Double Up has capacity limits, and the bill was moved to finance. Later, the committee advanced S.6286A, establishing an agricultural tax viability pilot program tied to agrivoltaics; supporters said it would address a need raised in recent hearings and work with farm groups, while Senator Borrello voted no. The final bill, S.7618 on food safety and quality date label requirements, drew debate over whether New York should act without a federal standard and whether the bill could create confusion or unintended costs, especially for dairy and other perishables. Supporters said the bill would reduce food waste and simplify the many existing date labels without forcing new labeling on those who do not already use it; members also discussed refrigeration references in the bill, and the sponsor said the language could be adjusted. The committee then adjourned and announced that future meetings will be held on the third floor in the new location.

Transcript Highlights:

• FDA.
• at the FDA to release this for 75 years."
• Has the FDA, CDC ever published any public guidance on DNA contamination in these shots?
• approved, like Vioxx, which was ultimately withdrawn despite being FDA approved.
• It built upon decades of foundation... research to develop the first FDA-approved mRNA vaccines.

Bills: HB18, HB37, HB116, HB18, HB37, HB116, HB388, HB879, HB913, HB1151, HB2216, HB2358, HB2809, SB577, SB1590, SB1782, SB1887, SB2744

Keywords: HB 18, Texas Legislature, quorum break, quorum-busting, legislative walkout, absent legislators, political contributions, campaign finance, political expenditures, legislative caucus, specific-purpose committee, Texas Ethics Commission, civil penalty, show cause order, district court, Fifteenth Court of Appeals, session fundraising, travel lodging food expenses, legislative session, compelled attendance

Transcript Highlights:

• Covered services include, but are not limited to, diagnostic testing, FDA-approved hormonal therapies
• What the changes do is make it more explicit that HRT treatment must be approved by the FDA to be covered
• Yes. and has an FDA approval, nor subject to prior authorization or step therapy requirements.
• What the changes do is to make it more explicit that HRT treatment must be approved by the FDA to be
• These include widely recognized and FDA approved treatments including hormone replacement therapy, early

Summary: The committee met with roll call attendance and took up two bills. First was Senate Bill 315 with Senate Amendment 1, which would allow the Division of Small Business to add state funding to existing federal small business programs, including the Small Business Innovation Research and Small Business Technology Transfer programs. There was brief public support from one in-person commenter, no virtual comment, and the committee voted to release the bill, though it did not yet have enough signatures for immediate release and was left open for absent members to sign. The second item was Senate Substitute 1 for Senate Bill 319, a women’s health insurance mandate requiring coverage for medically necessary menopause and perimenopause diagnostic and treatment services, including FDA-approved hormone replacement therapy, pelvic floor therapy, and related care. Representative Smith presented the bill as a response to gaps in menopause care and insurance coverage, and Department of Insurance witness Kennedy Cook explained the religious exemption as applying to certain religious employers and blanket health policies. Committee members asked about the scope of that exemption, and some expressed concern about religious carveouts, while others praised the bill as important women’s health legislation. During public comment, one speaker supported the bill but warned that expanding mandatory health benefits can raise insurance costs. The Department of Insurance then testified in support, saying the bill would align Delaware with other states, many insurers already comply, and the department did not expect a meaningful premium impact. The committee voted to release Senate Substitute 1 for Senate Bill 319 from committee.

Transcript Highlights:

• Because the FDA makes sure it's safe.
• Triannual State evaluation from FDA.
• So, our authority is granted from FDA.
• FDA falls under the Department of Health and Human Services.
• We have the contract inspector because, For those inspectors, FDA provides them.

Bills: SB2122, SB330, SB2071, SB2169, SB2069, SB2095, SB2157

Keywords: poultry, agriculture, out-of-state processing, Oklahoma Department of Agriculture, regulation, food safety, elk population, wildlife management, Oklahoma State University, veterinary medicine, ecosystem health, habitat assessment, milk, dairy, dairy farm, milk products, Grade A milk, pasteurization, raw milk, milk inspection

Transcript Highlights:

• <03:09:20.960> approved scientifically tested and FDA approved scientifically tested and FDA
• the section 3 to the FDA, making a small carve-out for FDA-approved technologies.
• So I would have concerns with tying state law to the FDA for that reason.
• Section 3 to the FDA, and to tying the section 3 to the FDA, making a small carve-out for FDA-approved
• So I would have concerns with tying state law to the FDA for that reason.

Keywords: 1189, house, all

Transcript Highlights:

• Uh so as a little process at the FDA.
• , it's already been approved by the FDA, it's already been approved by the FDA, they<03:32:29.920
• There are disease areas in for the FDA.
• all definitions straight from FDA all definitions straight from FDA regulations.<03:52:10.319>
• The second ahead of the FDA timeline.

Keywords: 1189, house, all

Transcript Highlights:

• has clearly stated um which the FDA has clearly stated there's<00:15:50.240> no<00:15:50.440>
• of this morning the FDA has only authorized<00:16:01.120> 34<00:16:01.560> ecigarettes
• The FDA has been publishing a list of authorized e-cigarette products for years, and currently there
• The FDA has been publishing a list of authorized e-cigarette products for years, and currently there
• The FDA has been publishing a list of authorized e-cigarette products for years, and currently there

Keywords: 912, senate, all

Summary: The Senate Committee on Commerce and Consumer Protection held decision-making on SB 146, SB 147, and SB 1166. SB 146 and SB 147, both relating to condominiums, were recommended to pass with amendments. The committee adopted amendments based on testimony from Anne Anderson, including mediator/arbitrator qualifications, clarifications about disputes involving managing agents, small claims timing, lien rights, and refund determinations by an early neutral evaluator. For both bills, the effective date was deferred to July 1, 2050 for further discussion. Each measure was adopted with no objections. SB 1166, relating to insurance, was also passed with amendments. The committee removed language that would have required insurers to bring claims and condition rates on doing so, replacing it with encouraging language. The amended bill adds a private cause of action against responsible parties, authorizes insurer actions under certain conditions, defines terms tied to climate-related events and fossil fuel products, and requires HPIA to report to the insurance commissioner on whether it exercised direct action rights. The effective date was likewise deferred to July 1, 2050, and the measure was adopted without objection. The committee then heard SB 985, relating to consumer protection and gift card fraud, and SB 1525, relating to electronic smoking devices and e-liquids. SB 985 drew support from a consumer fraud victim and others who said gift card scams disproportionately harm kupuna, while the Retail Merchants of Hawaii opposed the bill’s packaging/display requirements and suggested stronger penalties instead. The committee voted to pass SB 985 with amendments, deferring its effective date to July 1, 2050, and noted it would move on to Judiciary next. SB 1525 drew significant opposition from the Attorney General’s office, Department of Taxation, Department of Health, and public health groups, who argued it conflicted with federal tobacco law, was hard for Tax to administer, and would not effectively remove unauthorized vape products. After testimony, the committee recommended deferral of SB 1525 without objection.

Transcript Highlights:

• As our regulators at the FDA determined, that was the case with PMI's iOS product. Thank you again.
• While it's been noted that they received a modified risk designation from the FDA, the FDA notes that
• The FDA Tobacco Product Scientific Advisory...
• I've studied nicotine and tobacco for about 25 years, holding positions at the NIH and the FDA.
• The FDA has done an extensive review, years long, of millions of... extensive review, years long, of

Bills: HB30, HB263, HB357, HB359, SB60, SB102, HB30

Keywords: elections, post-election audit, election audit, risk-limiting audit, ballot audit, election integrity, voter confidence, Secretary of State, judge of probate, canvassing board, poll watchers, ballot containers, manual tally, recount, county election, statewide election, general election, absentee ballots, provisional ballots, election transparency

Transcript Highlights:

• to generate funding for FDA approval. to generate funding for FDA approval.
• The estimated total cost for FDA The estimated total cost for FDA approval<00:19:05.440> is
• Texas is in the FDA approves drugs.
• The FDA will not expect ibogaine to be 100% safe.
• The FDA will not expect is 100% safe.

Keywords: 958, all

Summary: The committee first reviewed preferred administrative regulations and, hearing no concerns, considered them reviewed. It then took up House Bill 388, described as a Casper cleanup bill. The sponsor said it would exempt charitable health care providers from e-prescribing requirements, allow Casper data sharing with certain federal entities, update references to hydrocodone’s schedule status, clean up drafting errors, and clarify practitioner registration with Casper. The bill passed 9-0 and was then approved for consent. Next, House Bill 134 was presented as a follow-up to a prior study on shortages of sexual assault nurse examiners and SANE-ready hospitals. The sponsor and a representative from the Kentucky Association of Sexual Assault Programs said the bill would create a statewide SANE coordinator. The committee adopted a substitute, then passed the bill unanimously and sent it to consent. Senate Bill 147 was then heard as an administrative update to vital records, modernizing certified-copy requests, adjusting fees, and requiring the Cabinet for Health and Family Services to send the annual death report to the State Board of Elections by July 1 each year. It passed unanimously and was also moved to consent. House Bill 280, a Kentucky Board of Nursing cleanup bill, would let the board investigate out-of-state nurses applying for Kentucky licenses, clarify licensing language, and update school rescue medication provisions, including inhalers, nebulizers, glucagon, Solu-Cortef, and nasal epinephrine. A committee substitute narrowed the bill to glucagon updates, and one senator asked whether the bill also covered child care centers; the sponsor said it addressed school medications only but was open to further discussion. The bill passed 10-0 and was reported favorably. Finally, Senate Bill 77 drew extended testimony. The sponsor and supporters argued that ibogaine research and treatment could help address addiction, PTSD, and depression, citing studies, personal recovery stories, and a proposed public-private partnership funded through opioid settlement money. The committee substitute removed the bill’s appropriation request and emergency clause, and members asked questions about whether PTSD is an addiction, whether smoking was included, whether the bill was authorizing research rather than funding, and how the treatment works. The sponsor said the substitute was only creating a structure for research, not appropriating money, and supporters described ibogaine as a one-time, medically supervised treatment. The transcript cuts off before a final vote on Senate Bill 77 is shown.

Transcript Highlights:

• Just really quickly, doctors are in charge at the FDA.
• So is ivermectin an FDA approved drug? Dr. Oliverson: Yes. Mr.
• Oliverson: That is what it is currently FDA approved for. Mr.
• Wu: The medicine as you just discussed is FDA approved for Mr.
• It's FDA approved for parasitic infections.

Bills: HB25, HB48, HB149, HB254, HB26, HB192

Keywords: ivermectin, pharmacist authority, prescription-free, healthcare regulation, patient access, HB 48, Texas alert notification systems, emergency alerts, public warning systems, alert fatigue, notification fatigue, Texas Division of Emergency Management, Department of Public Safety, DPS alerts, emergency management, State of Texas Emergency Assistance Registry, STEAR, disaster notifications, weather alerts, Amber Alert

Transcript Highlights:

• So can you commit to applying CDC, FDA standards when a...
• And one example is something called East Shore, which was FDA approved.
• And is that approved by the FDA?
• FDA, to my knowledge, is not yet FDA, to my knowledge, has not yet explored what Dr.
• I'm very concerned about your not wanting to follow FDA and CDC guidelines.

Summary: The committee first considered the confirmation of Dr. John Lattell to the Florida Board of Medicine. In questioning, senators focused heavily on his views on abortion, vaccines, ivermectin, hormonal birth control, and the role of CDC/FDA guidance in board discipline cases. Dr. Lattell said the board should apply Florida statutes, described himself as strongly pro-life and skeptical of some federal health guidance, and said he would be sympathetic when judging fellow physicians because of his own experience in practice. Supporters praised his medical background, military service, and family medicine experience, while opponents argued his stated views could affect his ability to fairly discipline other doctors. The committee voted 5-2 to recommend confirmation, with Senators Polsky and Rouson voting no. The committee then took up the confirmation of Taylor Hatch as Secretary of the Florida Department of Children and Families. Hatch outlined her background at DCF and APD and described department priorities including streamlining services, improving child welfare and behavioral health systems, expanding peer support, and reducing SNAP error rates. Members asked detailed questions about Hope Florida, the number and role of Hope Navigators, agency responsiveness on bill analyses, and accountability for community-based care contractors. Hatch said Hope Florida is a partnership-based navigation effort aimed at self-sufficiency, that 143 Hope Navigators are in place, and that the department is working to improve transparency and oversight through contracts, audits, and a proposed funding model. Senators also pressed Hatch on the Hope Florida Foundation’s compliance history and on forensic audits of community-based care agencies, especially Northwest Florida Health Network. Hatch said the foundation is now in compliance and under audit, and that the contractor had completed corrective actions and was operating within current accountability limits. She said DCF had not yet conducted new forensic audits under her tenure but was preparing another round and was considering using contracted-services dollars to support that work. The discussion ended with continued questioning on oversight, staffing, and whether the agency could provide more formal bill analyses going forward.

Transcript Highlights:

• yet fully approved with the FDA. yet fully approved with the FDA.
• physician be uh infor informed of FDA physician be uh infor informed of FDA approved<00:10:31.120
• FDA might refer to as a plausible FDA might refer to as a plausible mechanism,<00:38:53.839> which
• FDA.
• So ultimately I want to be more FDA than the FDA when we get to phase three.

Keywords: 1189, house, all

Transcript Highlights:

• We participated, or we collaborated with the FDA last year, in an evidence synthesis.
• So what we did for FDA was to synthesize available evidence on benefits as well as harms.
• This reporting platform is actually similar to what the FDA does for prescription medications.
• So we use the same methods that the FDA is using and classifying these reports.
• I have spent more than 10 years on the FDA Drug Safety and Risk Management Advisory Committee.

Summary: The Health Professions and Program Subcommittee met to receive oversight briefings on Florida’s medical marijuana program from the Department of Health’s Office of Medical Marijuana Use (OMMU) and from the University of Florida’s Consortium for Medical Marijuana Clinical Outcomes Research. OMMU Director Christopher Kimball outlined the program’s structure, including more than 900,000 active patients, nearly 7,000 caregivers, 27 MMTC licensees, 706 dispensing locations, and nine certified testing labs. He described the state’s pre-approval process for products and advertising, plain packaging requirements, seed-to-sale tracking, registry operations, and compliance efforts such as background checks, inspections, complaint investigations, and lab desk audits. He also said the Bureau of Public Health Laboratories in Jacksonville had been accredited to begin supporting testing. Members asked about telehealth, patient growth, product safety, advertising to children, inspections, and the status of MMTC licensure; Kimball said recertifications by telehealth now make up more than half of recertifications, that patient growth has slowed, and that ongoing litigation is delaying issuance of 22 new MMTC licenses. Kimball also discussed implementation of recent legislation and licensure changes, including licenses issued under HB 387 and SB 1582 to applicants from the original Pigford-related pool, with additional cure opportunities still ongoing. He said the department is monitoring diversion, inversion, and unapproved products, and that it coordinates with law enforcement when needed but does not itself have sworn authority. In response to questions, he said the department does not regulate physicians directly, but may refer concerns to the Division of Medical Quality Assurance, and that caregiver and physician participation requirements are set by statute. Members raised concerns about edibles, child access, and continued use of child-attractive branding; Kimball said the department tries to catch issues through pre-approval and enforcement, and that complaints involving children are treated as serious and investigated using available records and camera footage. Dr. Almond Winterstein then presented the consortium’s research overview. He explained that the consortium was created by statute in 2019, includes 10 universities, and is funded by annual state appropriations. He said its work includes grants, a research repository, a clinical core, outreach, and evidence synthesis, including a recent FDA-supported review of cannabis evidence. He emphasized that the current evidence base is limited and often low quality, with the strongest signals for symptom relief in PTSD-related symptoms, nausea, and some pain outcomes, but with many studies inconclusive or mixed. He also described the consortium’s use of registry data linked to Medicaid, Medicare, death, fetal death, and birth records to study safety and outcomes, including children, pregnancy, driving safety, opioid-sparing effects, and adverse events. Winterstein said adverse event reporting is sparse and likely underreported, with most reports mild but some serious events noted, and he expressed concern about use among young adults because of uncertain benefit-risk and possible effects on the developing brain. The committee discussed the need for better surveillance, more robust adverse event reporting, and the possibility of using linked data to identify harms more quickly. At the end of the meeting, the committee rose without objection.

Transcript Highlights:

• Sydney Greenberger: And the FDA will play a role in determining the safety and efficacy of these systems
• The FDA evaluated over 965 reports...
• The FDA evaluated over 965 reports of harm, including 264 deaths.
• I'd also like to mention that even melatonin is not FDA approved because the FDA does not approve supplements
• FDA director without kratom and 7-OH.

Bills: HB305, HB395, HB341

Keywords: hemp, marijuana, THC regulations, cannabis products, adult-use industry, public health, youth protection, child support, reunification, Department of Services for Children, family court, liability

Summary: The committee met in late June with Senators Hansen, Buckson, Siegfried, Townsend, and Huxable present, and first approved the meeting minutes by voice vote. The opening bill, HB 341, would limit DFS from filing child support in foster care cases unless doing so would not hinder reunification; Children’s Department staff said the department has already decided to stop filing in all such cases, with an estimated fiscal impact of about $140,000 annually. Public testimony from the League of Women Voters supported the bill as a compassionate measure to help families reunite. The committee then heard HB 446/related anaphylaxis legislation for colleges and universities, which would allow institutions to stock and use intranasal epinephrine alongside auto-injectors and update training and reporting requirements. The Asthma and Allergy Foundation of America supported the measure, emphasizing the need for needle-free options and faster treatment of anaphylaxis. The committee also took up HS1 for HB 356 on PFAS, which would ban firefighting foam containing PFAS beginning in 2028, require disclosure if PPE contains PFAS, and address recalls; DNREC and the fire service supported it, saying most departments have already transitioned away from PFAS foam. A major portion of the meeting focused on HB 305, a diabetes wellness pilot program that would use continuous glucose monitoring, app-based care coordination, lab testing, and DHIN data analysis to shift care toward prevention and remission. Sponsor Senator Siegfried described the bill as a response to Delaware’s high diabetes costs and prevalence, and the Medical Society of Delaware supported it as a proactive model. The committee also discussed HB 395, which would regulate intoxicating hemp-derived products and synthetic cannabinoids by classifying products over a THC threshold as marijuana and creating penalties for unlicensed sales; the Office of the Marijuana Commissioner supported the bill, while hemp industry representatives and Senator Hoffner warned it could harm legitimate hemp retailers and access to hemp products. The final item, HS1 for HB 332, would ban sales and marketing of kratom products to those under 21 and direct the state to study testing and regulation of kratom and synthetic variants. Supporters, including the Delaware Healthcare Association and several recovery advocates, said age-gating is a reasonable first step and that synthetic products are the main concern; opponents and some senators argued the bill should go further and fully ban kratom or better distinguish synthetic products from natural leaf kratom. No formal roll-call votes were taken on the substantive bills during the transcript, and the meeting adjourned after public comment.

Transcript Highlights:

• It's FDA-approved, and it is used in sedation for animal species.
• It's FDA-approved, and it is used in sedation for animal species.
• It's FDA-approved, and it is used in sedation for animal species.
• It's FDA-approved, and it is used in sedation for animal species.
• It is typically obtained from FDA-licensed and regulated distributors.

Keywords: 995, all

Summary: The special commission on xylazine met virtually to review and discuss the first draft of its final report. Chair Mindy Domb opened the meeting, confirmed quorum, and the commission approved the minutes from its December 11 public meeting. Staff then walked commissioners through the proposed report structure, including background on xylazine as both an FDA-approved veterinary drug and an illicit drug supply contaminant, as well as appendices for public meeting materials and public resources. The commission discussed findings and recommendations for several working groups. For oversight and enforcement, members focused on licit versus illicit sources of xylazine, noting that the illicit supply is typically obtained through online vendors rather than diverted from veterinary use. Recommendations included better storage and reporting practices in authorized settings, review of manufacturing and distribution information, and focusing enforcement on fentanyl trafficking and large-scale xylazine importation rather than personal possession. Commissioners also discussed whether xylazine should remain in Schedule 6 or be subject to additional penalties, and several members emphasized the need for coordination, information-sharing, and possibly a DPH task force or advisory body to monitor emerging drug threats. For outreach and treatment, staff summarized strong existing programs such as drug checking, wound care education, naloxone distribution, mobile and low-threshold care, and self-directed wound kits, while noting gaps including the lack of an FDA-approved reversal agent for xylazine, difficulty distinguishing xylazine from other exposures, and uneven access by geography, insurance, and audience. Commissioners stressed the need for provider education, including physicians, nurses, pharmacists, family support networks, and first responders, and for clear guidance on wound care and when more intensive treatment is needed. The education and training section identified first responders, clinicians, non-clinicians, and people who use drugs and their families as key audiences for tailored, stigma-free materials, with emphasis on real-time, centralized data, naloxone and breathing support, recognition of overdose versus xylazine exposure, and adapting materials as the drug supply changes. The meeting ended with discussion of next steps: staff will circulate a revised draft by March 2, the commission will meet again on March 9 to consider the report and recommendations, and an additional late-March meeting was reserved if needed before the statutory deadline.

Transcript Highlights:

• But we're contracted with the FDA to go out and investigate these kinds of things.
• I mean, we rarely fail FDA stings.
• You don't mess with the FDA.
• We have the FDA with science, right? Like, okay, so we have federal stuff based on science.
• The USDA, as people have mentioned, the FDA regulates all tobacco products, including vapes.

Keywords: 959, house, all

Summary: The Commerce Committee reconvened to continue testimony on House Bill 2085, which would preempt local regulation of the sale of tobacco, nicotine, and vapor products and establish a statewide standard. The bill sponsor and supporters repeatedly said the measure is intended to create uniform rules for retailers, protect small businesses from a patchwork of local ordinances, and preserve existing local zoning authority. Several members questioned whether the bill’s language was too broad or vague, especially as to whether it could affect zoning near schools or other sensitive locations, and the sponsor said zoning was not the intent and should remain local. Testimony in support came from representatives of the Missouri Vape and Alternative Products Association, Ware Brands, Warrant’s, the Missouri Grocers Association, Maverick Convenience Stores, and the Missouri Petroleum Marketers and Convenience Store Association. Supporters argued that local flavor bans or other restrictions would harm small businesses, create compliance problems, and push sales into neighboring jurisdictions. They also said federal Tobacco 21 rules already govern sales to minors, and that the bill should be read as a statewide sales standard rather than a public health measure. One supporter emphasized that retailers already comply with FDA enforcement and that inconsistent local rules create operational burdens. Opposition came from the Missouri Public Health Association and the Springfield-Greene County Health Department, which said local tobacco regulations have helped prevent youth smoking and that the bill could invite litigation over existing ordinances and limit future local public health action. Committee members raised concerns about local control, public health, and the bill’s wording, while the sponsor clarified that the bill would preempt state and local standards on the sale of tobacco products where the state has already acted, but would not require every locality to adopt a 21-year-old purchase age. An informational witness from MOST Policy Initiative described health risks associated with vaping, flavored products, and youth nicotine use. The hearing concluded without a vote, and the committee adjourned after taking all testimony.

Transcript Highlights:

• Abortion pills have been FDA approved for over 20 years. Did y'all know? that?
• And I would also stress that the FDA, we've heard the FDA invoked a number of times, does not recommend
• By the FDA under this risk evaluation and mitigation strategy.
• So that's the FDA that we've been talking about.
• You might also be interested to know that the studies the FDA relies on are.

Bills: SB 8, SB 1, SB 2, SB 5, SB 10, HB27, HB7, HB17, HB1, SB 9, SB 7, SB 17, SB 4, HB20, HB18, HB7, HB17, HB1, HB20, HB18, SB9, SB7, SB17, SB4, SB1, SR85, SR87, SB8, SB5, SB2, SB10, HB27

Keywords: sex designation, restroom access, civil penalties, private civil right of action, women's privacy, campground safety, youth camp regulations, flood safety, emergency evacuation, health and safety standards, disaster relief, flood preparedness, emergency funding, local government support, meteorological forecasting, abortion, healthcare, jurisdiction, civil action, qui tam

Transcript Highlights:

• Um, having skimmed a little bit of the letter from the FDA Advocate, it says the FDA develops medication
• Um, having skimmed a little bit of the letter from the FDA Advocate, it says the FDA develops medication
• This document is an FDA document.
• <00:25:36.679> um FDA um FDA um document<00:25:38.760> um<00:25:39.200> I<00:25:
• <00:33:16.679> information to provide some FDA information to provide some FDA information

Keywords: 1189, house, all

Transcript Highlights:

• We don't need it yet, but if we do, FDA has already given us clearance on that.
• I'm not familiar with what Barry Engelheim is trying to have approved by the FDA.
• These must be FDA approved.
• Hold USDA and FDA and other federal partners accountable. I think they're doing a good job.
• Hold USDA and FDA and other federal ...congressional delegation, hold USDA and FDA and other federal

Summary: The joint hearing focused on preparedness for the New World screwworm threat and brought together the House Committees on Culture, Recreation, and Tourism and Agriculture and Livestock. USDA officials, Texas Department of Agriculture Commissioner Sid Miller, and Texas Animal Health Commission leadership described the pest as a serious risk to livestock, wildlife, rural economies, and beef prices, and emphasized coordination among federal, state, industry, and Mexican partners. Witnesses repeatedly stressed that Texas is currently seeing no confirmed U.S. detections, but that recent confirmed cases in northern Mexico, including Nuevo León, remain a concern because of their proximity to the border. USDA testimony outlined current surveillance and response efforts, including more than 120 screw worm-specific traps along the Texas border and neighboring states, thousands of additional dual-purpose traps, wildlife inspections, weekly coordination with Mexico’s Senasica, and a new USDA New World Screwworm Directorate. Officials said the existing Panama sterile fly facility is maxed out at about 100 million flies per week, while a dispersal facility in Tampico is helping move flies farther north in Mexico. They also described plans for a retrofitted sterile fly facility in Metapa, Mexico, expected to come online in 2026, and a new domestic production facility at Moore Air Base, with phase one targeted for late 2026 or early 2027 and phase two adding substantially more capacity later. Members pressed USDA on timelines, production capacity, the reliability of Mexican reporting, the risk from wildlife, and whether modular or mobile facilities could be deployed faster. USDA said it is also exploring innovative technologies, including a genetically engineered sterile male fly, but that such tools still require EPA review and field validation. Commissioner Miller highlighted Texas biosecurity efforts, five permanent inspection stations, cooperation with FDA and EPA on treatments such as Exzolt, and other pest issues affecting Texas agriculture. He also noted research into fly bait and private-sector efforts to speed sterile fly production. Texas Animal Health Commission officials described extensive state preparedness work, including weekly coordination calls, field response trainings, outreach to producers and veterinarians, and a Texas Screwworm Response Team. They said Texas has trained more than 100 inspectors and other personnel, with additional trainings planned, and that the state is expanding its cattle fever tick rider program. No votes or formal committee actions were taken during the hearing; the main action was the exchange of testimony and questions about readiness, surveillance, and facility timelines.

Transcript Highlights:

• Um that's the drugs are FDA approved.
• , safety information required by the FDA, safety information required by the FDA, conducting<01:05
• uh registered or inspected by the FDA. uh registered or inspected by the FDA.
• you're saying is that if the FDA you're saying is that if the FDA approved<01:08:31.520> drugs
• ingredients are even required FDA ingredients are even required FDA approval.<01:09:37.759> And

Keywords: Public Health and Welfare - Room 216, 3 February, 2026; 3:00 PM, 925, all

Summary: The committee met with a quorum and first took up several bills described as vehicles to keep options open for pending rural health issues, especially the rural health transformation fund and the Greenwood Hospital situation. The chair explained that Greenwood Hospital is struggling financially and operationally, including a Medicaid overpayment dispute in which Medicaid planned to recoup $2 million from a December payment, threatening payroll and continued operation. The committee discussed a proposed committee substitute that would delay recoupment until May 1 and preserve legislative flexibility to help Greenwood if a workable plan emerges. The committee adopted motions for title sufficiency and due pass on the block of bills, including the committee substitute and reverse repealer provisions. The committee then turned to two certificate-of-need bills. One bill, 2474, was presented as a rural hospitals measure that would let certain rural hospitals obtain certificates of need for services such as outpatient dialysis units, ambulatory surgical facilities, and geriatric psychiatric units, with definitions aimed largely at Delta and other rural counties. The chair also included a provision making the state health officer’s licensing decision final and not subject to judicial review, with only a short reconsideration process available. Senator Hill objected, arguing the bill concentrated too much power in the health department, eliminated meaningful court review, and unfairly picked winners and losers instead of letting the market work. The chair responded that the goal was to reduce costly, repetitive litigation and preserve access to care in areas where hospitals struggle financially. The committee then considered Senator Blackwell’s broader CO bill, which would address appeals and litigation more generally by shifting costs to the losing party in CO disputes. A reverse repealer was adopted first, and the chair explained that the bill was intended to reduce endless and expensive appeals while still allowing a limited opportunity for reconsideration. Senators Hill and others raised concerns about limiting judicial review and expanding health department power, while the chair said many states have no judicial review in this area and that the committee was exploring the issue further. The chair said he had asked several members to study the matter and contact the National Council of State Legislatures. The committee ultimately adopted the motions on the bills and amendments by voice vote, with the ayes prevailing each time.